DGAP-Adhoc: VITA 34 International AG: Q1 2009 in line with plans

VITA 34 International AG / Quarter Results

15.04.2009 

Release of a Adhoc News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------

* Storage at 2,448 units in line with previous year levels 
* Sales of EUR 3.4 million, EBIT at EUR -0.2 million
* Full year 2009 confirmed, target EBIT break even 

Leipzig, April 15, 2009 - Vita 34 International AG (ISIN DE000A0BL849), the
parent company of the leading umbilical cord blood bank in the G/S/A region
VITA 34, stored 2,448 units of umbilical cord blood in Q1 2009, very much
in line with the 2,453 units stored in the first quarter of previous year.
Sales in Q1 2009 reached EUR 3.4 million and as anticipated were slightly
below previous year levels of EUR 3.6 million. Earnings before interest and
taxes (EBIT) improved to EUR -0.2 million after EUR -0.3 million in the
previous year's quarter. This means that VITA 34 is on target for EBIT to
break-even in the full year 2009. The equity ratio came in at around 62
percent as of March 31, 2009, remaining at a high level after 64 percent at
the end of the previous year's quarter.

Interest in storing umbilical cord blood has developed positively in the
last few months. In Q1 2009, VITA 34 saw enquiries increase by around 33
percent against Q4 2008. The number of enquiries is an indication of future
business development, and this in turn means that VITA 34 can expect
increasing sales in the medium to short-term.

VITA 34 concluded an agreement in Slovenia modelled on the successful
collaboration with Spanish cooperation partner Secuvita. The company
Izvorna celica will take over marketing and will teach staff in maternity
clinics how to extract umbilical cord blood. Storage is exclusively at VITA
34. Now all authorisations have been provided by the responsible
authorities and the first units are to be stored in Slovenia in Q2. VITA 34
is sticking to its plans to enter another European market for the storage
of umbilical cord blood in 2009.

The full quarterly report is available for download in the Investor
Relations section at www.vita34.de.



Media / Investor Relations:
Axel Mühlhaus
Dr. Sönke Knop
edicto GmbH
Zeißelstraße 19
D-60318 Frankfurt
Tel.:+49 (069) 90550550
Fax: +49 (069) 90550577
Email: vita34@edicto.de






DGAP 15.04.2009 
---------------------------------------------------------------------------
Language:     English
Issuer:       VITA 34 International AG
              Deutscher Platz 5a
              04103 Leipzig
              Deutschland
Phone:        +49(0341)48792-40
Fax:          +49(0341)48792-39
E-mail:       info@vita34.de
Internet:     www.vita34.de
ISIN:         DE000A0BL849
WKN:          A0BL84
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, München, Stuttgart
End of News                                     DGAP News-Service
---------------------------------------------------------------------------